187 related articles for article (PubMed ID: 37498408)
21. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression.
Cai C; Peng X; Zhang Y
Bioengineered; 2021 Dec; 12(1):7007-7019. PubMed ID: 34551671
[TBL] [Abstract][Full Text] [Related]
23. Angiopoietin-like protein 2 decreases peritoneal metastasis of ovarian cancer cells by suppressing anoikis resistance.
Takeshita Y; Motohara T; Kadomatsu T; Doi T; Obayashi K; Oike Y; Katabuchi H; Endo M
Biochem Biophys Res Commun; 2021 Jul; 561():26-32. PubMed ID: 34000514
[TBL] [Abstract][Full Text] [Related]
24. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
[TBL] [Abstract][Full Text] [Related]
25. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
26. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
27. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
[TBL] [Abstract][Full Text] [Related]
29. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
30. Adipocytes fuel gastric cancer omental metastasis
Tan Y; Lin K; Zhao Y; Wu Q; Chen D; Wang J; Liang Y; Li J; Hu J; Wang H; Liu Y; Zhang S; He W; Huang Q; Hu X; Yao Z; Liang B; Liao W; Shi M
Theranostics; 2018; 8(19):5452-5468. PubMed ID: 30555557
[TBL] [Abstract][Full Text] [Related]
31. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
Mak CS; Yung MM; Hui LM; Leung LL; Liang R; Chen K; Liu SS; Qin Y; Leung TH; Lee KF; Chan KK; Ngan HY; Chan DW
Mol Cancer; 2017 Jan; 16(1):11. PubMed ID: 28095864
[TBL] [Abstract][Full Text] [Related]
33. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
34. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
37. Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis.
Fan H; Atiya HI; Wang Y; Pisanic TR; Wang TH; Shih IM; Foy KK; Frisbie L; Buckanovich RJ; Chomiak AA; Tiedemann RL; Rothbart SB; Chandler C; Shen H; Coffman LG
Cell Rep; 2020 Dec; 33(10):108473. PubMed ID: 33296650
[TBL] [Abstract][Full Text] [Related]
38. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
39. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract][Full Text] [Related]
40. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
